

1 **Title:** High-throughput CRISPR screens to dissect macrophage-*Shigella* interactions

2

3 **Authors:** Yong Lai^{1,2,3}, Liang Cui¹, John G. Doench⁴, & Timothy K. Lu^{1-7*}

4 **Affiliations:** ¹Antimicrobial Resistance Interdisciplinary Research Group, Singapore-
5 MIT Alliance for Research and Technology, Singapore; ²Synthetic Biology Group, MIT
6 Synthetic Biology Center, Massachusetts Institute of Technology (MIT), Cambridge,
7 MA, USA; ³Research Laboratory of Electronics, MIT, Cambridge, MA, USA; ⁴Broad
8 Institute, Cambridge, MA, USA; ⁵Department of Electrical Engineering and Computer
9 Science, MIT, Cambridge, MA, USA; ⁶Harvard-MIT Division of Health Sciences and
10 Technology, Cambridge, MA, USA; ⁷Department of Biological Engineering, MIT,
11 Cambridge, MA, USA.

12 *e-mail: timlu@mit.edu

13

14 **Shigellosis, the primary cause of diarrheal deaths worldwide, particularly affects**
15 **children living in low and middle-income countries¹. The causative agent, *Shigella***
16 **spp., invades and replicates in the epithelium of the large intestine, eliciting an intense**
17 **inflammatory response and tissue destruction². However, how *Shigella* rewires**
18 **macrophages prior to epithelial cell invasion³ is poorly understood. Here we show that**
19 ***Shigella flexneri* induces the production of pro-inflammatory cytokines and**
20 **chemokines and triggers host pyruvate catabolism for energy acquisition before**
21 **rapidly killing macrophages. To identify host factors modulated by *S. flexneri*, we**
22 **performed genome-wide and focused secondary CRISPR knockout and CRISPRi**

23 screens in human monocytic THP-1 cells infected with *S. flexneri* and evaluated host
24 cell survival. Knockdown of key components of the Toll-like receptor 1/2 signaling
25 pathway significantly reduced pro-inflammatory cytokine and chemokine production,
26 enhanced host cell survival, and controlled intracellular pathogen growth.
27 Knockdown of the enzymatic component of the mitochondrial pyruvate
28 dehydrogenase complex also enhanced THP-1 cell survival. Small molecule inhibitors,
29 which selectively inhibit key components of these pathways, enhanced host survival
30 and limited intracellular pathogen growth. High-throughput CRISPR screens
31 provide insights into the specific effects of *S. flexneri* on macrophages; these insights
32 can potentially guide development of new therapies for shigellosis.

33 Annually, there are more than one million cases of shigellosis¹. In 2016, over two
34 hundred thousand people were killed by shigellosis globally⁴. More than 65% of these
35 deaths occurred in children under 5 years old and in adults older than 70 years⁴, indicating
36 that the fully developed, healthy human immune system may be sufficient to prevent and
37 control *Shigella* infections. We therefore investigated susceptibility to this potentially
38 lethal bacterium at the cellular level, focusing on immune cells.

39 Infection is initiated when *Shigella* crosses the intestinal epithelium through
40 microfold cells (M cells)⁵. After transcytosis to the M cell pocket, *Shigella* targets the
41 resident macrophages, inducing caspase-1-dependent pyroptotic cell death, an essential
42 step to subsequent invasion and replication in the intestinal epithelium^{3,6}. Epithelial cells
43 constitute the major habitat of *Shigella*⁷. Within this replicative niche, *Shigella flexneri*
44 delivers various virulence proteins via a type III secretion system (T3SS), resulting in
45 weakened host defenses⁷. These virulence proteins reduce intracellular trafficking^{8,9},

46 antagonize caspase-4-dependent pyroptosis¹⁰, prevent necrosis mediated by mitochondrial
47 damage¹¹, and inhibit the early stage of apoptosis by p53 degradation¹². As a consequence,
48 epithelial cells survive infection and continue to harbor the bacteria¹²⁻¹⁴.

49 Whereas the effects of *Shigella* infection on epithelial cells have been studied
50 extensively, little attention has been paid to how *S. flexneri* interacts with macrophages,
51 although it has been demonstrated that this intracellular pathogen rapidly induces
52 macrophage pyroptosis by activating NLRP3- or NLRC4-inflammasomes¹⁵⁻¹⁷. To improve
53 our understanding of how *S. flexneri* manipulates macrophages and induces rapid cell death
54 and to identify host targets for potential therapy, we conducted CRISPR screens in human
55 macrophage-like THP-1 cells following infection with *S. flexneri*.

56 To examine whether *S. flexneri* infects and kills THP-1 cells, we first assessed the
57 phagocytosis of *S. flexneri* M90T by detecting the red fluorescence (*uhpT::dsRed*) induced
58 by host cell-produced glucose 6-phosphate¹⁸ and indicative of intracellular *S. flexneri*. We
59 then measured THP-1 cell viability post-infection (Extended Data Fig. 1). We found that
60 *S. flexneri*, at a multiplicity of infection (MOI) of 10:1, efficiently infected THP-1 cells and
61 induced host cell death 3 hours after infection (Extended Data Fig. 1a, d, e). Such infection
62 with *S. flexneri* can be utilized as selective pressure for subsequent host survival-based
63 genetic screens. Independent biological triplicates of genome-wide CRISPR knockout and
64 CRISPRi screen libraries were prepared in THP-1 cells expressing Cas9 and dCas9-Krab,
65 respectively¹⁹⁻²¹ (Extended Data Fig. 2). After *S. flexneri* infection, surviving THP-1 cells
66 with specific sgRNA barcodes were maintained in culture medium for continuous
67 replication and harvested for next generation sequencing and analysis. The distribution of
68 sgRNAs in *S. flexneri*-infected THP-1 cells was significantly different from that in

69 uninfected THP-1 cells (Extended Data Fig. 3). The results of genome-wide screens were
70 visualized with volcano plots (Fig. 1a, b).

71 In order to identify top positively selected genetic hits in *S. flexneri*-infected THP-
72 1 cells, we used a false discovery rate (FDR) of <0.25 and log₂ fold change of >1 as cut-
73 off points. Positive hits were considered those that extended the survival of the THP-1 cells
74 after 2-3 hours of bacterial infection. We observed positive selection of 76 and 28 genes in
75 CRISPR-Cas9 knockout and CRISPRi screens, respectively, with 10 genes enriched in
76 both screens (p-value <7.394E-18; Fig. 1c; Supplementary Tables 1 and 2). Pathway
77 analysis identified multiple enriched biological processes in *S. flexneri*-infected THP-1
78 cells. Both CRISPR-Cas9 knockout and CRISPRi screens identified the same pathways,
79 such as Toll-like receptor (TLR) cascades, chromatin organization, pyruvate catabolism,
80 the cellular stress response pathway, and receptor tyrosine kinase signaling (Fig. 1d, e;
81 Extended Data Fig. 4a, b). More specifically, all key components of the TLR1/2 signaling
82 pathway (TRAF6, IRAK1, IRAK4, MYD88, TLR1, TLR2, TIFA, TIRAP) were identified
83 in our genome-wide screens (Fig. 1f). Intriguingly, TRAF6 and TIFA also play important
84 roles in the ALPK1-TIFA-TRAF6-NF- κ B pathway, by which epithelial cells detect
85 lipopolysaccharide (LPS) biosynthetic intermediates and regulate inflammation in
86 response to them²²⁻²⁴. Yet, ALPK1, a newly identified cytosolic immune receptor in
87 *Yersinia pseudotuberculosis* and *S. flexneri* infection^{23,25}, was not a genetic hit in our
88 genome-wide CRISPR screens (Fig. 1f). Although *S. flexneri* causes NF- κ B-induced
89 inflammation in both macrophages and epithelial cells, it also exhibits distinct mechanisms
90 of host manipulation that may contribute to opposite outcomes of infection in these cell

91 types, i.e., rapidly induced cell death of macrophages but inhibited cell death of epithelial
92 cells⁷.

93 Moreover, the identification of genes involved in pyruvate catabolism (PDHB,
94 DLAT, CS, PDHA1, MPC1, MPC2; Fig. 1f) echoed the rerouting of carbon flux by *S.*
95 *flexneri* observed in HeLa cells²⁶, which supports the rapid growth of these bacteria in this
96 host. Intriguingly, key components of the NLRC4 and NLRP3 inflammasomes (AIM2,
97 CASP1, NLRC4, NLRP3, GSDMD, and NAIP) that are activated by *S. flexneri* T3SS
98 effectors MxiI¹⁷, IpaB²⁷, and IpaH7.8²⁸ in macrophages were identified as negative hits in
99 our genome-wide CRISPR screens (i.e., a gene whose knockout or knockdown shortened
100 THP-1 cell survival) (Fig. 1f), indicating that certain genes in the pyroptotic cell death
101 pathway may actually protect host cells in *S. flexneri* infection. Overall, our results indicate
102 the reliability of genome-wide CRISPR screens for studying *S. flexneri* infection and the
103 importance of comprehensively understanding macrophage-*S. flexneri* interactions.

104 We next designed and prepared secondary CRISPR knockout and CRISPRi screen
105 libraries targeting 372 human genes in order to validate genome-wide screen hits²¹, to test
106 genes that were associated with different types of host cell death, and to compare the
107 performance between CRISPR knockout and knockdown libraries by ensuring that there
108 were consistent numbers of sgRNAs per gene in each type of library. Similar to our
109 genome-wide screens, surviving THP-1 cells were harvested following *S. flexneri* infection,
110 and the results of the screens were visualized with volcano plots (Extended Data Fig. 5a,
111 b). We identified 23 and 29 genes in secondary CRISPR knockout and CRISPRi screens,
112 respectively, with 12 genes enriched in both screens (FDR<0.05; log₂ FC>0.5; p-
113 value<3.486E-09; Fig. 2a). To evaluate the reliability of our genome-wide CRISPR screens,

114 we calculated the validation rate of genes in secondary screens based on the FDR threshold
115 (<5%); these genes were clustered by their p-value in the genome-wide screens²⁰ (Fig. 2b).
116 The validation rate of screen hits in secondary CRISPR knockout and CRISPRi screens
117 decreased with increasing p-values in primary genome-wide screens. This result suggests
118 the reliability of genome-wide screens, which have lower numbers of sgRNAs per gene
119 than secondary screen libraries, for studying bacterial infections (Extended Data Fig. 2).
120 Furthermore, genome-wide top positive genetic hits were validated by secondary screens,
121 such as genes in the TLR1/2 signaling pathway (IRAK1, MYD88, TRAF6), the type I
122 interferon pathway (TYK2, IFNAR2, IRF8, STAT2), and the TNF receptor signaling
123 pathway (TNFRSF1A), suggesting the robustness of genome-wide screens (Fig. 2c;
124 Extended Data Fig. 5c; Supplementary Tables 3 and 4). Yet, genes involved in pyruvate
125 catabolism, such as PDHB and PDHA1, were not scored significantly in secondary screens
126 (Extended Data Fig. 5c); further validation of these genes would be required to confirm
127 their involvement in the infectious process. Positive screen hits that were identified by both
128 genome-wide and secondary screens were summarized based on the diverse signaling
129 pathways they are associated with in *S. flexneri* infection (Fig. 2d). Many positive genetic
130 hits with unknown functions in bacterial infection were also identified (PHF6, PHIP,
131 TRERF1, and MAP2K7).

132 Consistent with genome-wide CRISPR screens, components of inflammasomes
133 mediating pyroptosis in macrophages post-infection, such as NLRP3 and GSDMD, were
134 identified in our secondary screens as negative hits (Fig. 2d; Extended Data Fig. 5c). Yet,
135 genes involved in other types of host cell death, i.e., necrosis and apoptosis, did not show
136 consistent patterns of screen phenotypes and were not identified as genetic hits. Not

137 surprisingly, NOD1, a critical intracellular bacterial sensor, was identified as a negative hit
138 in the CRISPR knockout screen, indicating its protective role for host cells (Fig. 2d;
139 Extended Data Fig. 5c). Intriguingly, SOD1 and SOD2, which destroy free superoxide
140 radicals in host cells, were also identified as negative screen hits in *S. flexneri* infections
141 (Fig. 2d; Extended Data Fig. 5c); decreased expression of these genes may contribute to
142 necrosis induced by reactive oxygen species²⁹. Additionally, by calculating the sgRNA
143 correlation of replicates, signal/noise ratio, p-value, and FDR of CRISPR screens, we found
144 that CRISPR-Cas9 knockout and CRISPRi yielded comparable results in secondary
145 screens (Extended Data Fig. 6).

146 To further verify the function of top positive genetic hits, we next constructed THP-
147 1 cells with individual gene knockdowns and confirmed their phenotypes in *S. flexneri*
148 infection. The positive correlation between screen phenotype and validation phenotype
149 confirmed that repression of positive screen hits indeed enhanced host cell survival with a
150 92.3% true positive rate (Pearson R=0.56; Fig. 3a). Moreover, repression of the
151 transcription of MYD88, TRAF6, and IRAK1, key components in the TLR1/2 signaling
152 pathway, also inhibited intracellular *S. flexneri* growth (Fig. 3b).

153 To characterize how the inhibition of those positive genetic hits mediates the host
154 cell response and provides protection, we measured cytokine and chemokine production
155 regulated by the TLR1/2 signaling pathway (Fig. 3c). Knockdown of the transcription of
156 either MYD88 or IRAK1 abolished the production of infection-induced pro-inflammatory
157 cytokines and chemokines, such as IL-1 β , IL-2, and IL-8 (Fig. 3d; Extended Data Fig. 7a).
158 As a potential strategy to control intracellular bacterial infection by targeting host factors,
159 we tested the function of corresponding small molecule inhibitors. IRAK1/4-Inh, a

160 selective inhibitor of IRAK1, inhibited *S. flexneri* growth and pro-inflammatory cytokine
161 and chemokine production, and protected host cells in a dose-dependent manner (Fig. 3e,
162 f; Extended Data Fig. 7b-d). Ginsenoside Compound K (CK), a metabolite of Panax
163 ginseng that also inhibits IRAK1³⁰, similarly enhanced host cell survival, inhibited *S.*
164 *flexneri* growth, and abolished infection-induced IL-8 production in THP-1 cells (Extended
165 Data Fig. 8).

166 In addition to dysregulating the host immune response, *S. flexneri* grows rapidly
167 and replicates in host cells but does so only if there is an adequate supply of nutrients.
168 Knockout or knockdown of components of the pyruvate dehydrogenase complex or the
169 pyruvate transporter MPC1/2 in the mitochondria redirected central metabolism, favoring
170 the survival of THP-1 cells infected with *S. flexneri* (Fig. 2d, 4a), which is congruent with
171 the induction by *S. flexneri* in HeLa cells of the production of acetyl-CoA²⁶. We next tested
172 the function of the PDHB inhibitor oxythiamine (OT), as well as its combination with an
173 IRAK1 inhibitor (IRAK1/4-Inh), in *S. flexneri* infection. OT treatment enhanced host cell
174 survival post-infection (Fig. 4b) but failed to control intracellular *S. flexneri* growth (Fig.
175 4c), which is consistent with the PDHB gene knockdown phenotype (Fig. 3a, b).
176 Interestingly, the combination of both IRAK1 and PDHB inhibitors (IRAK1/4-Inh and OT)
177 significantly enhanced host cell survival and controlled *S. flexneri* growth better than
178 treatment with either of these inhibitors alone, indicating a synergistic effect of inhibitors
179 targeting both immune and non-immune pathways in macrophages (Fig. 4b, c).
180 Furthermore, in a PMA-stimulated THP-1- *S. flexneri* infection model, IRAK1/4-Inh, OT,
181 and their combination enhanced host cell survival and limited intracellular pathogen
182 growth (Fig. 4d-f).

183 In line with a previous study of HeLa cells²⁶, we found that *S. flexneri* induced
184 acetyl-CoA production in THP-1 cells, suggesting that, in both cases, *S. flexneri* supports
185 its own rapid intracellular growth and replication by manipulating the central metabolism
186 of the host cell (Fig. 4g). Moreover, 0.1 mM of PDHB inhibitor decreased infection-
187 induced acetyl-CoA and downstream succinate production, which shifts host metabolism
188 and leads to enhanced host cell survival (Fig. 4g, h). The combination of both IRAK1 and
189 PDHB inhibitors reduced acetyl-CoA and succinate production to the uninfected levels,
190 thus limiting intracellular *S. flexneri* growth and propagation (Fig. 4g, h).

191 Rapid macrophage death is prerequisite for *S. flexneri* to further infect and persist
192 in the surrounding epithelial cells, which ultimately results in diarrhea and even dysentery,
193 the most life-threatening manifestations of infection. However, unlike the intensive studies
194 of the effects of *Shigella* infection on epithelial cells, the comprehensive interactions
195 between *S. flexneri* and macrophages have been largely overlooked^{15-17,27,28}. Our study
196 highlights the capability of host cell survival-based CRISPR screens to elucidate complex
197 macrophage-pathogen interactions and to identify key cellular processes that are disrupted
198 by intracellular pathogens. In epithelial cells, NF- κ B-related inflammatory signaling is one
199 of the major defenses against *S. flexneri* infection^{23,24}. For instance, upon sensing ADP- β -
200 D-manno-heptose (ADP-Hep), epithelial cells activate NF- κ B signaling in their cytosol
201 and produce the pro-inflammatory chemokine IL-8. In response to these signals, *S. flexneri*
202 produces multiple virulence proteins, disrupting inflammation and preventing epithelial
203 cell death.

204 However, what occurs in epithelial cells does not necessarily occur in other cell
205 types. In fact, our study revealed effects of *S. flexneri* in macrophage-like THP-1 cells

206 distinct from those reported for *Shigella*-infected epithelial cells. In THP-1 cells, *S. flexneri*
207 also stimulated IL-8 production but did so by activating the TLR1/2 signaling pathway,
208 and infection induced rapid THP-1 cell death. Although the TLR1/2 pathway is well known
209 for its role in the innate immune response to invading pathogens via the recognition of
210 peptidoglycan and triacyl lipopeptides, the induced inflammation could contribute to
211 bacterial pathogenesis³¹. For instance, in *Burkholderia* infection, knockout of TLR2
212 enhances the survival of mice and reduces sepsis, compared to what was observed with
213 wild-type mice³². Moreover, blockade of both TLR2 and TLR4 with monoclonal antibodies
214 effectively inhibits *Escherichia coli* and *Salmonella enterica*-triggered immunopathology
215 and prevents mouse death³³. In our study, inhibiting the TLR1/2 signaling pathway in THP-
216 1 cells by IRAK1 inhibitors reduced pro-inflammatory cytokine and chemokine production,
217 enhanced THP-1 cell survival, and limited intracellular *S. flexneri* growth and replication,
218 indicating the detrimental effect of the TLR1/2 signaling pathway in immune cells during
219 *S. flexneri* infection. Considering the opposite effects of NF- κ B signaling when epithelial
220 cells and immune cells are infected with *S. flexneri*, modulating the inflammatory response
221 of the host as a therapeutic strategy should be very carefully considered.

222 It is well known that macrophage pyroptosis is triggered by *S. flexneri*, allowing
223 bacteria to escape from macrophages and invade epithelial cells⁷. But this process also
224 restricts intracellular bacterial pathogens by cytokine-independent mechanisms in a mouse
225 model³⁴ or by the direct antibacterial effect of GSDMD-NT (the N-terminal cleavage
226 product of GSDMD in pyroptosis)³⁵. It has been unclear whether pyroptosis protects the
227 macrophages or the intracellular bacteria. Our host genetic perturbation strategies provide
228 direct causal evidence that some of the genes that contribute to pyroptosis actually benefit

229 the host cells, since knockout or knockdown of key components of pyroptosis (GSDMD
230 and NLRP3) decreased host cell survival post-infection (Fig. 2d; Extended Data Fig. 5c).

231 Treatment for shigellosis is becoming increasingly difficult as resistance to most
232 inexpensive and widely used antibiotics becomes more prevalent³⁶. In order to reduce
233 mortality from diarrhea in children under 5 years of age to less than 1/1000 live births by
234 2025³⁷, current antibiotics will have to be complemented by other kinds of treatment, such
235 as host-directed therapies. Given that macrophages and epithelial cells appear to be
236 manipulated by *S. flexneri* in diametrically opposite ways, developing an adjuvant therapy
237 by targeting a common feature of those two types of host cells may be one way to block
238 bacterial pathogenesis. In this study, we demonstrated that by inhibiting infection-induced
239 acetyl-CoA production in host immune cells, the function of these cells can be restored and
240 energy acquisition by the intracellular pathogen can be limited (Fig. 4). In summary, our
241 study not only sheds new light on the mechanisms underlying macrophage-*S. flexneri*
242 interactions but also provides new insights to guide the development of adjuvant therapy
243 for shigellosis treatment.

244

245 **References**

- 246 1 Kotloff, K. L., Riddle, M. S., Platts-Mills, J. A., Pavlinac, P. & Zaidi, A. K. M.
247 Shigellosis. *Lancet* **391**, 801-812 (2018).
- 248 2 Schroeder, G. N. & Hilbi, H. Molecular pathogenesis of *Shigella* spp.: controlling
249 host cell signaling, invasion, and death by type III secretion. *Clin Microbiol Rev* **21**,
250 134-156 (2008).

- 251 3 Ashida, H. *et al.* *Shigella* deploy multiple countermeasures against host innate
252 immune responses. *Curr Opin Microbiol* **14**, 16-23 (2011).
- 253 4 Khalil, I. A., Troeger, T. & Blacker, B. F. Morbidity and mortality due to *Shigella*
254 and enterotoxigenic *Escherichia coli* diarrhoea: the Global Burden of Disease
255 Study 1990-2016. *Lancet Infect Dis* **18**, 1305-1305 (2018).
- 256 5 Wassef, J. S., Keren, D. F. & Mailloux, J. L. Role of M-cells in initial antigen
257 uptake and in ulcer formation in the rabbit intestinal loop model of shigellosis.
258 *Infect Immun* **57**, 858-863 (1989).
- 259 6 Ashida, H., Kim, M. & Sasakawa, C. Manipulation of the host cell death pathway
260 by *Shigella*. *Cell Microbiol* **16**, 1757-1766 (2014).
- 261 7 Ashida, H., Mimuro, H. & Sasakawa, C. *Shigella* manipulates host immune
262 responses by delivering effector proteins with specific roles. *Front Immunol* **6**, 219,
263 doi:10.3389/fimmu.2015.00219 (2015).
- 264 8 Ramel, D. *et al.* *Shigella flexneri* infection generates the lipid PI5P to alter
265 endocytosis and prevent termination of EGFR signaling. *Sci Signal* **4**, ra61,
266 doi:10.1126/scisignal.2001619 (2011).
- 267 9 Ferrari, M. L. *et al.* *Shigella* promotes major alteration of gut epithelial physiology
268 and tissue invasion by shutting off host intracellular transport. *Proc Natl Acad Sci*
269 *U S A* **116**, 13582-13591 (2019).
- 270 10 Kobayashi, T. *et al.* The *Shigella* OspC3 effector inhibits caspase-4, antagonizes
271 inflammatory cell death, and promotes epithelial infection. *Cell Host Microbe* **13**,
272 570-583 (2013).

- 273 11 Carneiro, L. A. *et al.* *Shigella* induces mitochondrial dysfunction and cell death in
274 nonmyleoid cells. *Cell Host Microbe* **5**, 123-136 (2009).
- 275 12 Bergounioux, J. *et al.* Calpain activation by the *Shigella flexneri* effector VirA
276 regulates key steps in the formation and life of the bacterium's epithelial niche. *Cell*
277 *Host Microbe* **11**, 240-252 (2012).
- 278 13 Niebuhr, K. *et al.* Conversion of PtdIns(4,5)P-2 into PtdIns(5)P by the *S. flexneri*
279 effector IpgD reorganizes host cell morphology. *Embo J* **21**, 5069-5078 (2002).
- 280 14 Pendaries, C. *et al.* PtdIns5P activates the host cell PI3-kinase/Akt pathway during
281 *Shigella flexneri* infection. *Embo J* **25**, 1024-1034 (2006).
- 282 15 Willingham, S. B. *et al.* Microbial pathogen-induced necrotic cell death mediated
283 by the inflammasome components CIAS1/Cryopyrin/NLRP3 and ASC. *Cell Host*
284 *& Microbe* **2**, 147-159 (2007).
- 285 16 Suzuki, T. *et al.* Differential regulation of caspase-1 activation, pyroptosis, and
286 autophagy via Ipaf and ASC in *Shigella*-infected macrophages. *PloS Pathog* **3**,
287 1082-1091 (2007).
- 288 17 Suzuki, S. *et al.* *Shigella* type III secretion protein MxiI is recognized by Naip2 to
289 induce Nlrc4 inflammasome activation independently of Pkc δ . *PLoS Pathog* **10**,
290 e1003926 (2014).
- 291 18 Runyen-Janecky, L. J. & Payne, S. M. Identification of chromosomal *Shigella*
292 *flexneri* genes induced by the eukaryotic intracellular environment. *Infect Immun*
293 **70**, 4379-4388 (2002).
- 294 19 Doench, J. G. *et al.* Optimized sgRNA design to maximize activity and minimize
295 off-target effects of CRISPR-Cas9. *Nat Biotechnol* **34**, 184-191 (2016).

- 296 20 Sanson, K. R. *et al.* Optimized libraries for CRISPR-Cas9 genetic screens with
297 multiple modalities. *Nat Commun* **9**, 5416, doi:10.1038/s41467-018-07901-8
298 (2018).
- 299 21 Lai, Y. *et al.* Illuminating host-mycobacterial interactions with functional genomic
300 screening to inhibit mycobacterial pathogenesis. *bioRxiv*, 2020.2003.2030.016139,
301 doi:10.1101/2020.03.30.016139 (2020).
- 302 22 Gaudet, R. G. *et al.* Innate recognition of intracellular bacterial growth is driven by
303 the TIFA-dependent cytosolic surveillance pathway. *Cell Rep* **19**, 1418-1430
304 (2017).
- 305 23 Garcia-Weber, D. *et al.* ADP-heptose is a newly identified pathogen-associated
306 molecular pattern of *Shigella flexneri*. *Embo Reports* **19**, doi:ARTN e46943
307 10.15252/embr.201846943 (2018).
- 308 24 Milivojevic, M. *et al.* ALPK1 controls TIFA/TRAF6-dependent innate immunity
309 against heptose-1,7-bisphosphate of gram-negative bacteria. *PLoS Pathog* **13**,
310 e1006224, doi:10.1371/journal.ppat.1006224 (2017).
- 311 25 Zhou, P. *et al.* Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial
312 ADP-heptose. *Nature* **561**, 122-126 (2018).
- 313 26 Kentner, D. *et al.* *Shigella* reroutes host cell central metabolism to obtain high-flux
314 nutrient supply for vigorous intracellular growth. *Proc Natl Acad Sci USA* **111**,
315 9929-9934 (2014).
- 316 27 Senerovic, L. *et al.* Spontaneous formation of IpaB ion channels in host cell
317 membranes reveals how *Shigella* induces pyroptosis in macrophages. *Cell Death*
318 *Dis* **3**, doi:ARTN e384 10.1038/cddis.2012.124 (2012).

- 319 28 Suzuki, S. *et al.* *Shigella* IpaH7.8 E3 ubiquitin ligase targets glomulin and activates
320 inflammasomes to demolish macrophages. *Proc Natl Acad Sci USA* **111**, E4254-
321 E4263 (2014).
- 322 29 He, S., Liang, Y., Shao, F. & Wang, X. Toll-like receptors activate programmed
323 necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway.
324 *Proc Natl Acad Sci U S A* **108**, 20054-20059 (2011).
- 325 30 Wee, Z. N. *et al.* IRAK1 is a therapeutic target that drives breast cancer metastasis
326 and resistance to paclitaxel. *Nat commun* **6**, 1-16 (2015).
- 327 31 Oliveira-Nascimento, L., Massari, P. & Wetzler, L. M. The role of TLR2 in
328 infection and immunity. *Front Immunol* **3**, 79, doi:10.3389/fimmu.2012.00079
329 (2012).
- 330 32 Wiersinga, W. J. *et al.* Toll-like receptor 2 impairs host defense in gram-negative
331 sepsis caused by *Burkholderia pseudomallei* (Meliodiosis). *PLoS Med* **4**, e248,
332 doi:10.1371/journal.pmed.0040248 (2007).
- 333 33 Spiller, S. *et al.* TLR4-induced IFN-gamma production increases TLR2 sensitivity
334 and drives Gram-negative sepsis in mice. *J Exp Med* **205**, 1747-1754 (2008).
- 335 34 Miao, E. A. *et al.* Caspase-1-induced pyroptosis is an innate immune effector
336 mechanism against intracellular bacteria. *Nature Immunology* **11**, 1136-U1194
337 (2010).
- 338 35 Liu, X. *et al.* Inflammasome-activated gasdermin D causes pyroptosis by forming
339 membrane pores. *Nature* **535**, 153-158 (2016).

- 340 36 Gu, B. *et al.* Comparison of the prevalence and changing resistance to nalidixic acid
341 and ciprofloxacin of *Shigella* between Europe-America and Asia-Africa from 1998
342 to 2009. *Int J Antimicrob Agents* **40**, 9-17 (2012).
- 343 37 World Health Organization & Unicef. *Ending preventable child deaths from*
344 *pneumonia and diarrhoea by 2025: The integrated Global Action Plan for*
345 *Pneumonia and Diarrhoea (GAPPD)*. World Health Organization: Geneva (2013).
- 346 38 Chen, S. *et al.* Genome-wide CRISPR screen in a mouse model of tumor growth
347 and metastasis. *Cell* **160**, 1246-1260 (2015).
- 348 39 Raudvere, U. *et al.* g:Profiler: a web server for functional enrichment analysis and
349 conversions of gene lists (2019 update). *Nucleic Acids Res* **47**, W191-W198 (2019).
- 350 40 Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: a
351 network-based method for gene-set enrichment visualization and interpretation.
352 *PLoS One* **5**, e13984, doi:10.1371/journal.pone.0013984 (2010).
- 353 41 Zhong, W. *et al.* Allosteric pyruvate kinase-based "logic gate" synergistically
354 senses energy and sugar levels in *Mycobacterium tuberculosis*. *Nat Commun* **8**,
355 1986, doi:10.1038/s41467-017-02086-y (2017).

356

357 **Methods**

358 **Reagents**

359 IRAK1/4-Inh (I5409), oxythiamine, and ginsenoside Compound K were purchased from
360 Sigma and used at the following concentrations: IRAK1/4-Inh, 0.1-10 μ M; Oxythiamine,
361 0.01-1 mM; Compound K, 1-25 μ M. Antibiotics in the media were at the following

362 concentrations: 100 $\mu\text{g ml}^{-1}$ ampicillin, 100 $\mu\text{g ml}^{-1}$ gentamicin, 100 U ml^{-1} Penicillin-
363 Streptomycin (Pen/Strep; Gibco).

364 **Mammalian cell culture**

365 The human monocyte cell line THP-1 was a gift from Jianzhu Chen (Singapore-MIT
366 Alliance for Research and Technology). HEK293FT cells were gifts from Asha Shekaran
367 (Engine Biosciences). THP-1 cells were cultured in RPMI1640 (HyClone) with 10% FBS
368 (Gibco) and Pen/Strep at 37°C with 5% CO_2 . 50 ng ml^{-1} phorbol 12-myristate 13-acetate
369 (PMA; Sigma) was used to differentiate THP-1 cells in tissue culture treated 96-well plates
370 (Corning). HEK293FT cells were cultured in Dulbecco's modified Eagle's medium
371 (DMEM) (HyClone) supplemented with 10% FBS and Pen/Strep at 37°C with 5% CO_2 .

372 **Bacterial strains and growth conditions**

373 *Shigella flexneri* M90T $\Delta virG$ pCK100 (*PuhpT::dsRed*), a gift from Cecile Arrieumerlou
374 (Institut Cochin), was grown in Lysogeny broth (LB) medium overnight at 37°C with
375 shaking. The next day, bacteria were diluted 1:100 into 10 mL LB medium and grown to
376 exponential phase for infection. When necessary, 100 $\mu\text{g ml}^{-1}$ ampicillin was added to the
377 growth medium.

378 ***In vitro* bacterial infection**

379 *S. flexneri* M90T $\Delta virG$ pCK100 were prepared in exponential growth phase for host cell
380 infection. THP-1 cells were infected at an MOI of 10 in complete RPMI1640 medium at
381 indicated times. To test the combination of IRAK1 and PDHB small molecule inhibitors,
382 THP-1 cells were infected at an MOI of 1:10. After *Shigella* infection, THP-1 cells were
383 treated with 100 $\mu\text{g ml}^{-1}$ gentamicin for 2 hours to kill extracellular bacteria. Subsequently,

384 host cells were washed and maintained for the rest of the experiments. Viable THP-1 cells
385 were counted in a hemocytometer by using trypan blue (Gibcon). Cell death of PMA-
386 stimulated THP-1 cells were measured by LDH assay (Takara).

387 **Enumeration of intracellular bacteria in infected cells**

388 At selected time points, 1 ml of *Shigella*-infected THP-1 cells were centrifuged and washed
389 twice with 1×PBS and then lysed with 50 µl of 1×PBS with 1% Triton 100. PMA-
390 stimulated THP-1 cell infected with *S. flexneri* were lysed with 50 µl of 1×PBS with 1%
391 Triton 100. 10-fold serial dilutions were performed followed by plating on LB agar plates
392 and incubated at 37°C for 24 hours. The number of viable intracellular bacteria was
393 calculated from the counted colony forming unit (CFU) on the agar plates.

394 **Pooled Genome-wide and secondary CRISPR Screens**

395 The Brunello human CRISPR knockout pooled library was obtained from Addgene
396 (#73178). The Dolcetto human CRISPRi pooled library was a gift from John Doench (the
397 Broad Institute, also available on Addgene #92385). Both secondary CRISPR knockout
398 and CRISPRi libraries, with 10 sgRNAs per gene, were designed to target the 251 genes
399 scored in primary genome-wide screens (133 of these genes were identified as being
400 involved in *S. flexneri* infection) and 121 genes from literature (47 of these genes were
401 found to be involved in *S. flexneri* infection)²¹. 1000 non-targeting sgRNAs were used as
402 controls²¹.

403 **Lentiviral library packaging**

404 Well dissociated HEK293FT cells were seeded at a density of 1.4×10^7 cells per flask in a
405 total volume of 35 ml of DMEM medium 24 h before transfection. Cells were optimal for

406 transfection at 80-90% confluency using 7 ml of Opti-MEM, 231 μ l of PLUS reagent, 210
407 μ l of Lipofectamine 2000, and a DNA mixture of 18.2 μ g of psPAX2 (Addgene #12260),
408 11.9 μ g of pMD2.G (Addgene #12259), and 23.8 μ g of library plasmid. Flasks were
409 incubated at 37°C with 5% CO₂ for 4 hours. The media was replaced with 35 ml DMEM
410 medium with 10% FBS and 1% BSA. Lentivirus was harvested 2 days after the start of
411 transfection and filtered through a 0.45 μ m polyethersulfone membrane.

412 **Lentivirus transduction**

413 To ensure that only one gene was targeted in each cell, Cas9- and dCas9-Krab-expressing
414 THP-1 cells were transduced with the pooled lentiviral CRISPR knockout and CRISPRi
415 libraries in three biological replicates at an MOI of 0.3, respectively. To ensure that each
416 perturbation would be fully represented and reduce spurious effects due to random genome
417 integration in the transduced cell population, screening libraries were prepared with
418 coverage of >500 cells per sgRNA. Lentiviral spinfection was performed by centrifuging
419 12-well plates at 1,000 g for 2 hours at 33°C with THP-1 cells grown in RPMI1640 medium
420 with 10% FBS and 8 μ g ml⁻¹ of polybrene. 24 hours after lentiviral transduction, cell culture
421 medium was replaced by RPMI1640 with 10% FBS and 2 μ g ml⁻¹ of puromycin for
422 selection. Following antibiotic selection, a library coverage of >3000 \times was maintained for
423 subsequent screens.

424 **CRISPR screens**

425 After puromycin selection, each CRISPR library replicate was split, one for *Shigella*
426 infection and one used as control to verify library representation. 100 μ g ml⁻¹ of gentamicin
427 was added to the cell culture to kill extracellular pathogen post-infection. Surviving host

428 cells were harvested and pelleted by centrifugation with coverage of >500 cells per sgRNA.

429 The pooled screens were performed as three independent replicates.

430 **Genomic DNA extraction, barcode amplification, next generation sequencing (NGS),**
431 **and analysis**

432 Genomic DNA (gDNA) from live THP-1 cells was isolated using a homemade modified
433 salt precipitation method as described previously³⁸. The sgRNA cassette was amplified by
434 PCR and prepared for Illumina sequencing (HiSeq2000) as described previously²⁰. The
435 sequencing reads were deconvoluted to generate a matrix of read counts, which were then
436 normalized under each condition by the following formula: $\log_2(\text{Reads per sgRNA}/\text{total}$
437 $\text{reads per condition} * 10^6 + 1)$. The \log_2 fold change of each sgRNA was determined by
438 comparing infected sample and uninfected samples for each biological replicate. A
439 CRISPR screen analysis tool developed by the Genetic Perturbation Platform (GPP) at the
440 Broad institute was used to evaluate the rank and statistical significance of genes
441 (<https://portals.broadinstitute.org/gpp/public/analysis-tools/crispr-gene-scoring>). A
442 hypergeometric distribution was used to calculate the overlap probability of screen hits
443 between CRISPR knockout and CRISPRi screens. Tests were carried out in R package
444 using the function `phyper(q, m, n, k, lower.tail=FALSE)`, where q is the number of overlap
445 genetic hits, m is the number of genetic hits identified by the CRISPR knockout screen, n
446 is the total number of genes in the library, and k is the number of genetic hits identified by
447 the CRISPRi screen. The g:Profiler tool³⁹ was used to perform gene-set enrichment
448 analysis based on genetic hits identified by CRISPR screens. The KEGG, Reactome, and
449 the Gene Ontology (Biological Process) were used as the pathway databases to identify
450 gene sets. Enrichment Map was used for interpretation of the biological processes⁴⁰.

451 **Validation of individual sgRNAs**

452 For each sgRNA cloning, spacer-encoding sense and antisense oligonucleotides with
453 BsmBI-compatible overhangs were synthesized, annealed, cloned into the lentiGuide-Puro
454 vector (Addgene #52963), and verified by sequencing (Supplementary Table 5). Lentivirus
455 was generated in HEK293FT cells using PLUS reagents and Lipofectamine 2000,
456 following manufacturer's instructions. Lentiviral transduction was performed in dCas9-
457 Krab-expressing THP-1 cells to generate individual gene knockdown THP-1 cells. After
458 11 days of puromycin selection, each individual gene knockdown THP-1 cell was infected
459 with *S. flexneri* to validate its phenotype, such as host cell survival and intracellular
460 pathogen growth, as a top positive genetic hit identified by the CRISPR screens.

461 **Cytokine quantification**

462 Supernatants of cell cultures were collected at indicated times post-bacterial infection.
463 Cytokine and chemokine levels in *S. flexneri*-infected supernatants were determined using
464 Bio-plex pro human cytokine 17-plex and IFN- α 2 kit (Bio-Rad) according to the
465 manufacturer's instructions. The results were measured by a Bio-Plex 200 system (Bio-
466 Rad).

467 **Metabolite profiling**

468 Metabolite extraction and targeted metabolomics analyses followed the published reports
469 with modifications⁴¹. Briefly, cell cultures were harvested at given time points and rapidly
470 quenched, and metabolites were extracted using acetonitrile:methanol:water (2:2:1). After
471 centrifugation, the supernatant was collected and evaporated to dryness in a vacuum

472 evaporator, and the dry extracts were redissolved in 100 μ L of 98:2 water/methanol for
473 liquid chromatography-mass spectrometry (LC-MS) analysis.

474 The targeted LC-MS/MS analysis was performed with Agilent 1290 ultrahigh
475 pressure liquid chromatography system coupled to a 6490 Triple Quadrupole mass
476 spectrometer equipped with a dual-spray electrospray ionization source with Jet StreamTM
477 (Agilent Technologies, Santa Clara, CA). Chromatographic separation of metabolites in
478 central carbon metabolism was achieved by using Phenomenex (Torrance, CA) RezexTM
479 ROA-Organic Acid H⁺ (8%) column (2.1 \times 100 mm, 3 μ m) and the compounds were eluted
480 at 40°C with an isocratic flow rate of 0.3 mL min⁻¹ of 0.1% formic acid in water.
481 Compounds were quantified in multiple reaction monitoring (MRM) mode. Electrospray
482 ionization was performed in both positive and negative ion modes with the following
483 source parameters: drying gas temperature 300°C with a flow of 10 L min⁻¹, nebulizer gas
484 pressure 40 psi, sheath gas temperature 350°C with a flow of 11 L min⁻¹, nozzle voltage
485 500 V, and capillary voltage 4,000 V and 3,000 V for positive and negative mode,
486 respectively. Data acquisition and processing were performed using MassHunter software
487 (Agilent Technologies, US), and cell counts were normalized to correct variations in
488 sample preparation.

489 **Imaging**

490 To visualize intracellular RFP-reporter *S. flexneri* M90T Δ *virG* (*uhpT::dsRed*), infected
491 THP-1 cells were directly observed under a confocal fluorescence microscope (Zeiss LSM
492 700).

493

494 **Acknowledgements**

495 We thank Karen Pepper for editing the manuscript. We thank Prof. Peter Dedon for
496 reviewing the manuscript. This work was supported by the United States Defense Threat
497 Reduction Agency (HDTRA1-15-1-0050 to T.K.L.), and the National Research
498 Foundation of Singapore through the Singapore-MIT Alliance for Research and
499 Technology AMR IRG (Y.L., L.C., T.K.L.)

500

501 **Author contributions** Y.L., L.C., J.G.D., and T.K.L. conceived and designed the research;
502 Y.L. and J.G.D. performed and analyzed genome-wide CRISPR screen experiments; Y.L.
503 and J.G.D. designed, performed and analyzed secondary CRISPR screen experiments; Y.L.
504 conducted validation experiments of genetic hits and small molecule inhibitors; Y.L. and
505 L.C. designed and performed metabolite profile experiments; Y.L. and T.K.L. coordinated
506 the overall research; T.K.L. supervised the overall research; Y.L., L.C., J.G.D., and T.K.L.
507 analyzed the data and wrote the manuscript. All authors discussed the results and reviewed
508 the paper.

509

510 **Competing interests**

511 T.K.L. is a co-founder of Senti Biosciences, Synlogic, Engine Biosciences, Tango
512 Therapeutics, Corvium, BiomX, and Eligo Biosciences. T.K.L. also holds financial
513 interests in nest.bio, Amplphi, IndieBio, MedicusTek, Quark Biosciences, and Personal
514 Genomics.

515 Y.L. and T.K.L. are co-inventors on a US provisional patent application (no. 62/909727),
516 which is based on discoveries described in this paper.

517

518 **Supplementary Information** is available in the online version of the paper.

519 **Correspondence and requests for materials** should be addressed to T.K.L.

520

521

522

523

524

525

526

527

528


529

530

531

532

533



534

535 **Fig. 1 Genome-wide pooled CRISPR knockout and CRISPRi screens to dissect**
 536 **biological pathways in *S. flexneri* infection.** **a** and **b**, Volcano plots from CRISPR
 537 knockout (**a**) and CRISPRi (**b**) screens. For each sgRNA-targeted gene, the x axis shows
 538 its enrichment (positive hits) or depletion (negative hits) post-infection, and the y axis

539 shows statistical significance measured by p-value. Top 3 positive and negative screen hits
540 are labeled as red and green dots, respectively. Gray dots represent non-targeting controls.
541 For each screen, experiments were carried out in triplicates. **c**, Enriched genes in Venn
542 diagram were filtered with a cut-off of FDR <0.25 and log₂ fold change >1 in *S. flexneri*
543 infection. The degree of significance of the overlap is given. **d** and **e**, Candidate genes
544 identified by CRISPR knockout and CRISPRi screens were functionally categorized to
545 understand the biological functions involved in *S. flexneri* infection. Edge width represents
546 mutual overlap of genes. Node size represents the number of genes in the gene set. Color
547 gradient of nodes represents the enrichment scores of gene-sets. **f**, Gene-centric
548 visualization of average log₂ fold change of CRISPR knockout and CRISPRi screens in *S.*
549 *flexneri*-infected versus non-infected host cells. Selected components of TLR1/2, pyruvate
550 catabolism signaling pathway, and inflammasome formation are highlighted in orange,
551 purple, and green.

552

553

554


555

556

557

558

559



560

561 **Fig. 2 Secondary CRISPR knockout and CRISPRi screens identify host genetic hits**

562 **in *S. flexneri* infection.** **a**, Enriched genes were filtered with a cut-off of FDR < 0.05 and

563 \log_2 fold change > 0.5 in *S. flexneri* infection. The degree of significance of the overlap is

564 given. **b**, Validation rate of genetic hits in the secondary screen grouped by their p-value

565 in the genome-wide screens in *S. flexneri* infection. Number of genes per category is

566 indicated. **c**, Genetic hits from both primary and secondary screens were ranked by their

567 differential gRNA abundance between *S. flexneri*-infected versus uninfected populations


568 (\log_2 fold change). **d**, Heatmap of screen hits clustered in different biological pathways in

569 *S. flexneri* infection.

570

571

572



573

574 **Fig. 3 Validation of top positive genetic hits and IRAK1 inhibitor in *S. flexneri***
 575 **infection of human THP-1 cells.** **a**, Correlation between pooled screen and validation data.
 576 For each hit, the log₂ fold change obtained from the genome-wide screening data (Screen
 577 phenotype) was plotted against the fold-change of cell viability of genetic hits compared
 578 to the non-targeting control cells (Validation phenotype). sgNC80 and sgNC135 are non-
 579 targeting controls. R is the Pearson correlation coefficient. **b**, Intracellular *S. flexneri* level
 580 after infection of individual knockdown THP-1 cells. **c**, Schematic of positive genetic hits
 581 in TLR1/2 signaling pathway and corresponding inhibitors. **d**, Cytokine and chemokine
 582 production in MYD88 and IRAK1 knockdown THP-1 cells post-infection. **e** and **f**, The
 583 viability of THP-1 cells (**e**) and intracellular *Shigella* growth (**f**) post-infection in the

584 presence or absence of IRAK1 inhibitor at different concentrations. Data represent the
585 mean \pm SD (n = 3) (two-tailed unpaired Student's *t*-test, * P<0.05 ** P<0.01 *** P<0.001;
586 ns represents not significant).

587

588

589

590

591

592

593

594

595

596

597


598

599

600

601

602



603

604 **Fig. 4 Validation of positive genetic hits in pyruvate catabolism signaling pathway**

605 **and corresponding inhibitor in *S. flexneri* infection of human THP-1 cells. a,**

606 **Schematic of positive genetic hits in pyruvate catabolism signaling pathway and**

607 **corresponding inhibitor. b and c, The growth of THP-1 cells (b) and intracellular *S. flexneri***

608 **level (c) post-infection in the presence or absence of different concentrations of PDHB**

609 **inhibitor (OT) and combined with IRAK1/4-Inh. d, Schematic of inhibitor validation in**

610 **PMA-stimulated THP-1 cell infected with *S. flexneri*. e, Effects of IRAK1 and PDHB**

611 **inhibitors on the survival of differentiated THP-1 post-infection, with death measured by**

612 **lactate dehydrogenase (LDH) release relative to the untreated condition. f, Effects of**

613 **IRAK1 and PDHB inhibitors on the growth of intracellular *S. flexneri* in differentiated**


614 **THP-1 cells. IRAK1/4-Inh is used at 10 μ M. OT is used at 0.1 μ M. g and h, Production of**

615 **acetyl-CoA (g) and succinate (h) with or without *S. flexneri* infection and in the presence**

616 **or absence of OT and combined with IRAK1 inhibitor. Data represent the mean \pm SD (b,**

617 **c, g and h, n = 3; e and f, n = 4) (two-tailed unpaired Student's *t*-test, * P<0.05 ** P<0.01**

618 ***** P<0.001 **** P<0.0001; ns represents not significant; N.D represents not detectable).**



619

620 **Extended Data Fig. 1 Optimization of conditions for *Shigella* infection of THP-1 cells.**

621 **a**, *S. flexneri* infection at an MOI (number of bacterial cells per host cell) of 10, from 0.5

622 hour to 5 hours incubation with THP-1 cells (Scale bar, 20 μ m). **b-e**, The number of

623 *Shigella*-infected THP-1 cells after 0.5 to 5 hours infection. More than 90% of host cells


624 were killed after 3 hours of infection (**d**). N.D represents not detectable. Data represent

625 mean \pm SD (n = 3) (two-tailed unpaired Student's *t*-test, * P<0.05 ** P<0.01 *** P<0.001;

626 ns represents not significant).

627

628



629

630 **Extended Data Fig. 2 Strategy for preparing CRISPR screen libraries and**

631 **performing positive screens.** Monoclonal Cas9 and dCas9-Krab-expressing THP-1 cell

632 lines were constructed and transduced with lentiviral sgRNA libraries²¹. High coverage

633 CRISPR knockout and CRISPRi libraries were split for subsequent *S. flexneri* infection.

634 Surviving THP-1 cells with sgRNA barcodes were harvested and processed for next

635 generation sequencing. Genome-wide genetic hits were identified by comparing sgRNA

636 abundance between infected samples and non-infected controls. Based on those host targets,

637 secondary CRISPR knockout and CRISPRi screen libraries were designed and prepared²¹.

638 Similarly, secondary positive screens were performed to validate those host targets. Finally,


639 drug inhibitors which selectively inhibit genetic hits were tested.

640

641

642

643



644

645 **Extended Data Fig. 3 sgRNA distribution of CRISPR knockout and CRISPRi**

646 **screening. a-c,** Distribution of individual sgRNA in control and *S. flexneri*-infected

647 samples after CRISPR knockout screens. **d-f,** Distribution of individual sgRNA in control

648 and *S. flexneri*-infected samples after CRISPRi screens. Each point represents individual

649 sgRNAs. Boxes, 25th to 75th percentile; Whiskers, 1st to 99th percentile.

650

651

652

653

654

655

656

657

a CRISPR KO screen		b CRISPRi screen	
Biological pathways	p-value (-log10)	Biological pathways	p-value (-log10)
Regulation of IFNA signaling	7.2	Chromatin organization	5.9
Toll-Like receptors cascades	7.2	Toll Like Receptor 2 (TLR2) Cascade	5.4
Class I MHC mediated antigen processing & presentation	6.2	PI3K/AKT activation	5.4
Pyruvate metabolism	6.0	RHO GTPases activate WASPs and WAVEs	5.1
Chromatin organization	5.9	Signaling by SCF-KIT	4.6
RHO GTPases activate WASPs and WAVEs	5.6	Signaling by FGFR	4.5
NOTCH1 intracellular domain regulates transcription	5.2	Cellular responses to stress	4.5
Transcriptional regulation by TP53	5.2	Transcriptional regulation by TP53	3.7
Regulation of pyruvate dehydrogenase (PDH) complex	5.0	Regulation of actin dynamics for phagocytic cup formation	3.6
Signaling by SCF-KIT	4.8	mTORC1-mediated signaling	3.6
PI3K/AKT activation	3.8	Fcγ receptor (FCGR) dependent phagocytosis	3.4
Signaling by FGFR	3.8	TNFs bind their physiological receptors	3.4
Regulation of actin dynamics for phagocytic cup formation	3.8	Pyruvate metabolism and TCA cycle	3.0
Cellular responses to stress	3.8	Cytosolic sensors of pathogen-associated DNA	2.7
Circadian clock	3.4	Circadian clock	2.7
Signaling by TGF-beta receptor complex	3.4	Mitochondrial biogenesis	2.5
Defensins	2.3	TNFR2 non-canonical NF-κB pathway	2.4
Metabolism of amino acids and derivatives	1.6	Regulation of lipid metabolism PPARα	2.3

658

659 **Extended Data Fig. 4 Enrichment of biological pathways identified by genome-wide**

660 **CRISPR knockout and CRISPRi screens in *S. flexneri* infection of THP-1 cells. a and**

661 **b, Gene enrichment analysis of positive genetic hits identified by CRISPR knockout screen**

662 **(a) and CRISPRi screen (b) in *S. flexneri* infection (FDR<0.1 and log2 FC>1).**

663

664


665

666

667

668

669



670

671 **Extended Data Fig. 5 Genetic hits identified by secondary CRISPR screens in *Shigella***

672 **infection. a and b, Volcano plots from secondary CRISPR knockout (a) and CRISPRi (b)**

673 **screens. For each sgRNA-targeted gene, the x axis shows its enrichment (positive hits) or**

674 **depletion (negative hits) post-infection, and the y axis shows statistical significance**

675 **measured by p-value. Top 3 positive and negative screen hits are labeled as red and green**

676 **dots, respectively. Gray dots represent non-targeting controls. For each screen, experiments**

677 **were carried out in triplicate. c, Gene-centric visualization of average fold change of**

678 **secondary screens in *S. flexneri*-infected versus non-infected host cells. Selected**

679 **components of TLR 1/2 signaling pathway, pyruvate catabolism, inflammasome formation,**

680 and type I interferon signaling pathway are highlighted in orange, purple, green, and pink,
681 respectively.

682

683

684

685

686

687

688

689

690

691

692

693


694

695

696

697

698



699

700 **Extended Data Fig. 6 Comparison of secondary CRISPR knockout and CRISPRi**

701 **screens in *S. flexneri* infection. a-d, sgRNA-level correlation of replicates in CRISPR**

702 knockout screens (**a** and **b**) and CRISPRi screens (**c** and **d**). Pearson correlation of log₂
703 fold change values between replicates is indicated. **e** and **f**, Top 50 positive genetic hits
704 (red) and non-targeting controls (gray) identified by CRISPR knockout (**e**) and CRISPRi
705 (**f**) in *S. flexneri* infection. Broken lines show the means of the hits (M_{signal}) and non-
706 targeting controls (M_{bckg}). **g** and **h**, p-value (**g**) and FDR (**h**) of top 100 positive genetic hits
707 identified by CRISPR knockout and CRISPRi screens in *S. flexneri* infection.

708

709

710

711

712

713

714

715


716

717

718

719

720



721

722 **Extended Data Fig. 7 Cytokine and chemokine production in THP-1 cells in *S. flexneri***

723 **infection. a**, Cytokine and chemokine production in THP-1 cells with or without *S. flexneri*

724 **infection. b-d**, Production of IL-1 β (**b**), IL-2 (**c**), and IL-8 (**d**) in THP-1 cells in the presence

725 of IRAK1 inhibitor at different concentrations. Data represent the mean \pm SD (n = 3) (two-


726 tailed unpaired Student's *t*-test, * P<0.05 ** P<0.01 *** P<0.001; ns represents not

727 significant).

728

729

730



731

732 **Extended Data Fig. 8 Validation of IRAK1 inhibitor Compound K in *Shigella***
 733 **infection. a**, Survival of THP-1 cells post-infection in the presence or absence of different
 734 concentrations of Compound K (CK). **b**, Intracellular *S. flexneri* growth in the presence or
 735 absence of different concentrations of CK. **c**, Production of infection-induced IL-8 in the
 736 presence or absence of different concentrations of CK. **d**, The growth of THP-1 cells in the
 737 presence or absence of CK without *S. flexneri* infection. Data represent the mean \pm SD (n
 738 =3) (two-tailed unpaired Student's *t*-test, * P<0.05 ** P<0.01; ns represents not significant).